ArticleBiologics : targets & therapy2012
Role of vandetanib in the management of medullary thyroid cancer.
Article in Biologics : targets & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Why 90% of clinical drug development fails and how to improve it?Acta pharmaceutica Sinica. B · 2022Review
- Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.Theranostics · 2018Review
- Lentivirus-mediated silencing of MPHOSPH8 inhibits MTC proliferation and enhances apoptosis.Oncology letters · 2016Article
- Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids.Molecules (Basel, Switzerland) · 2016Article
- Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.International journal of pediatric endocrinology · 2015Article
- Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects.Arquivos brasileiros de cardiologia · 2014Article
- Cabozantinib for progressive metastatic medullary thyroid cancer: a review.Therapeutics and clinical risk management · 2014Review
- UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.Molecular cancer therapeutics · 2013Article
- Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.Cancer medicine · 2013Article
- Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.International journal of endocrinology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma (MTC). In the last decade, small-molecule tyrosine kinase inhibitors (TKI) have been introduced in the field of thyroid cancer, after having been shown effective in a wide variety of other tumors. This review focuses on vandetanib (ZD6474, Zactima™; AstraZeneca) and its role in the treatment of MTC. Vandetanib is an oral TKI that targets VEGF receptors 2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. This drug has been tested in two important phase II studies which demonstrated that both the 100 and 300 mg/day dosage of vandetanib have antitumor activity on advanced MTC. A phase III trial (ZETA trial) evaluating vandetanib in 331 patients with locally advanced or metastatic MTC showed a significant prolongation of PFS for patients receiving vandetanib compared with placebo. Toxicity surveillance in all studies reported high rates of adverse effects with diarrhea, rash, fatigue and nausea being the most commonly experienced by patients. Vandetanib is currently approved in the United States for unresectable locally advanced or metastatic MTC and has become a new standard of care in this rare and indolent pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.